Related Experiment Video
Updated: Apr 5, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M)
Diana Santos1,2, Teresa Coelho3, Miguel Alves-Ferreira1,2
1UnIGENe, IBMC, Institute for Molecular and Cell Biology, and Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal.
Abstract:
Familial amyloid polyneuropathy (FAP) ATTRV30M is a neurodegenerative disorder due to point mutations in the transthyretin gene, with V30M being the commonest. FAP ATTRV30M shows a wide variation in age at onset (AO) between clusters, families and generations. Portuguese patients also show remarkable AO differences between genders. Genes found to be associated with FAP ATTRV30M pathways may act as AO modifiers. Our aim was to further explore the role of APCS and RBP4 genes and to study for the first time the involvement of sex-linked genetic modifiers - AR and HSD17B1 genes - in AO variation in Portuguese families. We collected DNA from a sample of 318 patients, currently under follow-up. A total of 18 tagging SNPs from APCS, RBP4, AR and HSD17B1 and 5 additional SNPs from APCS and RBP4 previously studied were genotyped. To account for nonindependency of AO between members of the same family, we used generalized estimating equations (GEEs). We found that APCS and RBP4 were associated with late AO. In addition, rs11187545 of the RBP4 was associated with an early AO. For the AR, in the male group three SNPs were associated with an early AO, whereas in the female group four were associated with both an early and later AO. These results strengthened the role of APCS and RBP4 genes and revealed for the first time the contribution of AR genes as an AO modifier in both males and females. These findings may have important implications in genetic counseling and for new therapeutic strategies.
Insights
Genetic variations in APCS, RBP4, and AR genes influence the age of onset for Familial Amyloid Polyneuropathy ATTRV30M, offering insights for genetic counseling and therapies.
Area of Science:
- Genetics
- Neurology
- Molecular Biology
Background:
- Familial amyloid polyneuropathy (FAP) ATTRV30M, caused by transthyretin gene mutations, exhibits significant variability in age of onset (AO).
- Previous research suggests genetic modifiers influence FAP ATTRV30M's AO, with notable gender-based differences observed in Portuguese populations.
Purpose of the Study:
- To investigate the role of APCS and RBP4 genes in modifying AO for FAP ATTRV30M.
- To examine the involvement of sex-linked genes, specifically AR and HSD17B1, as AO modifiers in Portuguese FAP ATTRV30M families.
Main Methods:
- Genotyping of 18 tagging SNPs from APCS, RBP4, AR, and HSD17B1, plus 5 additional SNPs from APCS and RBP4.
- Utilized generalized estimating equations (GEEs) to analyze age of onset data from 318 FAP ATTRV30M patients, accounting for familial non-independency.
Main Results:
- APCS and RBP4 gene variants were associated with later age of onset.
- A specific RBP4 SNP (rs11187545) was linked to an earlier age of onset.
- AR gene SNPs demonstrated associations with both early and late age of onset in both male and female patients.
Conclusions:
- The study confirms the role of APCS and RBP4 as AO modifiers in FAP ATTRV30M.
- It provides the first evidence for the AR gene's contribution to AO variation in both sexes.
- These findings have potential implications for genetic counseling and the development of targeted therapeutic strategies for FAP ATTRV30M.
More Related Videos
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenomics: Identification of New Drug Targets
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...